Gilead Sciences, Inc.
333 Lakeside Drive
Tel: 800-GILEAD-5 or 650-574-3000
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
Please click here for clinical trial information.
1477 articles with Gilead Sciences, Inc.
12/20/2018Gilead Sciences, in two days, inked two collaboration deals with two different companies that could pay out an aggregate of more than $3.125 billion. One of those deals is in the area of immuno-oncology, the other in fibrosis.
Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases
Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases.
12/17/2018With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.
With the closure of another year just weeks ahead, this time of year is one that many people use to take a look behind and see what lessons were learned over the past 12 months. For the world of biopharma, it’s also important to see what lessons have been learned.
Mr. O’Day Brings Global Pharmaceutical Leadership Experience Across Geographies and Therapeutic Areas
Gilead Sciences officially announced that long-time Roche veteran, Daniel O’Day, will assume the helm of the company as chairman and chief executive officer beginning March 1. O'Day takes over for John Milligan, who announced his plans to retire by the end of the year in July.
The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.
China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Fixed-Dose Combination HIV Treatment Backbone Can Be Paired with Range of Third Agents
12/3/2018The American Society of Hematology Annual Meeting is always chock full of interesting research and development stories. Here’s a look at some of the highlights of the meeting so far, which is continuing today.
Tesaro, located in Waltham, Mass., is rumored to be up for sale. The rumors caused shares to rocket as much as 39 percent on Friday, but it’s not the first time rumors have floated that the company might be on the auction block.
Today Bob Hilliard filed a lawsuit against Gilead, claiming the giant drug company intentionally kept a safer HIV drug from hundreds of thousands of patients so as to protect its multi-billion dollar patent on a less safe drug.
Chicago-based AbbVie just announced new data for its Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.
Webcast Available Through Gilead Corporate Website
11/12/2018As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials has taken four experimental vaccines to the front lines and begun to administer it to patients who may have been exposed to the deadly virus.
Data Demonstrate Sofosbuvir-Based Regimens Achieve High Cure Rates in Hepatitis C Patient Populations with Unmet Need
Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018
Phase 2 Data Presented on Investigational FXR Agonist GS-9674 in NASH
Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018
GS-9674 Granted Orphan Drug Designation by the U.S. Food and Drug Administration
Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018
Data Reinforce Breadth of Cell Therapy Portfolio and Commitment to Continued Innovation for People with Advanced Cancers
Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies
Global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer.
The deal, which will last several years, has Tango performing target discovery and validation. Gilead will be able to option rights to up to five targets that come out of Tango’s work.